Intraperitoneal injection of CXCL13 also enhanced the anti-tumor effect of anti-PD-1 treatment depending on the infiltration of CXCR5+ CD8+ T cells in high-grade serous ovarian cancer mice (87). This evidence concerns the gene CXCL13 and ovarian serous adenocarcinoma.